| Drug Type Small molecule drug | 
| Synonyms APL-1898, APL1898, JS-111 + [1] | 
| Target | 
| Action inhibitors | 
| Mechanism EGFR exon 20 inhibitors(EGFR exon 20 Mutation inhibitors) | 
| Therapeutic Areas | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| Drug Highest PhasePhase 1/2 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Recurrent Non-Small Cell Lung Cancer | Phase 2 | China  | 30 Apr 2025 | |
| EGFR-mutated non-small Cell Lung Cancer | Phase 2 | China  | 28 Apr 2025 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China  | 14 Jul 2021 | |
| EGFR positive non-small cell lung cancer | Phase 2 | China  | 14 Jul 2021 | |
| Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China  | 13 Jul 2021 | |
| EGFR ex20ins mutation in non-small cell lung cancer | IND Approval | China  | 22 Feb 2021 | 





